Marvel Biosciences Corp. to Present at the Life Sciences Investor Forum November 14th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
CALGARY, Alberta, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp.(TSX:V MBCOF:OTC), based in Calgary, Alberta, focused on Alzheimer’s Disease, Depression and Autism today announced that Dr. Mark Williams, CSO will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, on November 14th, 2024.
DATE: November 14thTIME: 10:30 AM ETLINK: https://bit.ly/3NuUDa4Available for 1x1 meetings: November 14 and 15
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
- Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome
Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.
Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:MARVEL BIOSCIENCES CORP.Dr. Mark WilliamsCSO431-777-7759mark@marvelbiosciences.com
Virtual Investor ConferencesJohn M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group(212) 220-2221johnv@otcmarkets.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.